LL-37
Regulatory
Legal Status in 2026
No FDA approval for human use in the US; sold only as a research chemical.
This compound has no FDA approval for human use in the United States and is not available through licensed US pharmacies or compounding channels. It has not completed the clinical trials required for FDA approval. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards. Always consult a physician.
About
About LL-37
LL-37 is the only member of the cathelicidin family of human antimicrobial peptides, with broad-spectrum activity against bacteria, viruses, and fungi. Beyond its antimicrobial role it is a potent immunomodulator and wound-healing agent with emerging anti-cancer properties. It is studied for chronic infections, biofilm disruption, and inflammatory conditions. Available as a compounded peptide.
Science
Mechanism of Action
Disrupts microbial cell membranes via electrostatic interactions, while also binding LPS to neutralize endotoxin; in host cells it activates toll-like receptors and chemokine receptors to coordinate immune responses.
Dosing
Typical Protocol
100 mcg subcutaneous injection once daily; intranasal and topical formulations used for localized applications.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Availability
Provider availability
LL-37 has no FDA approval for human use and is not available through licensed US prescribing or compounding channels, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.